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Interleukin-5 (IL-5) is the main eosinophilic cytokine that promotes the differentiation, 
survival, and activation of eosinophils, which are the key inflammatory cells in severe 
eosinophilic asthma (1, 2).
 
Thus, it is no surprise that anti-IL-5 pathways have been explored for 
several years for their ability to reduce eosinophilic inflammation and thus to improve the 
treatment of this disease (3, 4). 
Two anti-IL-5 monoclonal antibodies are now registered (mepolizumab and reslizumab), and 
one anti-IL-5 Rα antibody (benralizumab) (5) is on its way to registration. Other anti-eosinophilic 
agents acting through different mechanisms are also being explored, e.g., the anti-IL-13 
monoclonal antibody lebrikizumab (6), the anti-IL-4 receptor-α antibody dupilumab (7), the 
CRTh2 antagonists
 
fevipiprant (8) and tezepelumab, a human monoclonal antibody specific for 
the epithelial cell-derived cytokine thymic stromal lymphopoietin (9). 
Mepolizumab is a humanized monoclonal antibody that targets the IL-5 ligand and inhibits IL-
5 receptor signaling in eosinophils. Mepolizumab reduces exacerbation and asthma symptoms, 
improves lung function,
 
and reduces oral corticosteroid use in oral steroid-dependent patients with 
severe asthma (10). Reslizumab is a humanized anti-IL-5 monoclonal antibody that also targets the 
IL-5 ligand (11), reduces asthma exacerbations, and increases lung function (FEV1) in severe 
eosinophilic asthmatics (≥400 cells/µL) (12). 
 
Whereas mepolizumab is administered subcutaneously (SC) at a fixed dose (100 mg SC every 4 
weeks, Q4W), reslizumab is administered as a weight-adjusted intravenous dose of 3 mg/kg Q4W. 
No direct comparison of efficacy and safety between these two treatments has been reported before. 
Mukherjee et al. (13) compare mepolizumab and reslizumab in 10 prednisone-dependent asthmatics 
(sputum eosinophils >3% and blood eosinophils >300 cells/µL), who had previously received 
mepolizumab (100 mg SC Q4W) for at least 1 year. Patients received two infusions of placebo 
(Q4W) followed by four infusions of 3.0 mg/kg reslizumab Q4W in a single-blind, placebo-
controlled sequential trial. Primary outcomes were reductions of blood and sputum eosinophils; 
additional outcomes included clinical and functional parameters and some exploratory biomarkers. 
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Mukherjee et al. (13) found that weight-adjusted intravenous reslizumab was superior to fixed-dose 
SC mepolizumab in attenuating airway eosinophilia in these prednisone-dependent asthmatics, and 
that this effect was associated with better asthma control. 
This was a small study—more a proof-of-concept, hypothesis-generating study—that 
nonetheless provides clinically relevant information. It was conducted in oral steroid-dependent 
patients with severe eosinophilic asthma, the most difficult population to manage. Results clearly 
showed that a fixed-dose treatment is inferior to a weight-adjusted dose, although there is no 
information on the difference in potency between mepolizumab and reslizumab or the different 
effects of various forms of administration. The study has the strength of coming from a group that 
has unique experience in sputum eosinophil analysis and in the management of steroid-dependent 
patients with severe eosinophilic asthma. Although conducted in only 20 steroid-dependent 
asthmatics—9 treated with mepolizumab and 11 treated with placebo (14)—their previous pivotal 
study has helped to reverse the idea that mepolizumab is useless in asthma (15) unless a very select 
group at risk of exacerbations is treated and unless exacerbations are chosen as the primary outcome 
of the study.    
The present study also has the merit of investigating the potential mechanism and the 
complexity of local immunologic processes leading to an effective blockade of IL-5 activities and 
eosinophilic inflammation at the tissue level. Indeed, airway eosinophilopoiesis, immune complex 
formation, and autoimmune mechanisms were explored as possible pathways of IL-5 treatment 
when local IL-5 dosage is inadequate. Thus, the authors provide information on the reasons that 
make severe asthma non- or less responsive to high-dose corticosteroids and shed new light on the 
importance of the immunologic events that occur when the monoclonal antibody reaches and 
confronts its specific target. Likewise, the authors highlight the need for studies that address the 
pharmacokinetics/pharmacodynamics of airway bioavailability of monoclonal antibodies in patients 
with severe asthma. Previously, data have been obtained only in patients with mild asthma; thus, we 
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have missed potentially important considerations for the appropriate clinical use of these drugs in 
terms of both effectiveness and safety (3, 4).  
The study has several limitations, which are acknowledged by the authors. In particular, for 
ethical reasons, the comparison of the effects between the two treatments is not balanced. The 
changes between post-mepolizumab and pre-mepolizumab were assessed and compared with the 
differences between changes from baseline of post-reslizumab versus post-placebo. This is not 
always statistically irrelevant: For equivalency, pre- and post-mepolizumab should have been 
compared with pre- and post-reslizumab. If so, from a statistical viewpoint, reslizumab would 
appear less effective for FEV1 (Figure 3A), and the difference between treatments would not be so 
clear-cut for some of the effects on eosinophilic inflammation (Figure 4). Indeed, there is often a 
deterioration during the placebo treatment that is sometimes close to statistical significance (Figure 
3A). This makes the uneven design of the study questionable, and its conclusions require a follow-
up from properly designed and powered studies. Finally, although not statistically significant (p= 
0.06, 0.07), the differences between the two study arms in blood/sputum eosinophils at baseline are 
quite consistent. (The percentage of sputum and blood eosinophils in the mepolizumab arms on 
average half that in the reslizumab arm, a substantially different starting point for the primary 
objective assessed in the study.) 
The clinical conclusion of the study is that we have to learn to use these new expensive 
monoclonal antibodies without knowing their pharmacokinetics and pharmacodynamics, or their 
biological concentration and effect on the target cells in the target organs. The criteria for use 
(and/or reimbursement) will be based only on clinical elements (severity, use of resources, 
pharmacologic treatment, circulating eosinophils, response to other pharmacologic treatments). In 
other words, as often happens in medicine, we will have to learn to do without knowing enough. 
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